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Abstract
Background: Influenza is an under-appreciated cause of acute lower respiratory infections (ALRI) in children. It is
estimated to cause approximately 20 million new episodes of ALRI in children annually, 97% of these occurring in
developing countries. It is also estimated to result in 28000 to 112000 deaths annually in young children. Apart
from hospitalisations and deaths, influenza has significant economic consequences. The current egg-based
inactivated influenza vaccines have several limitations: annual vaccination, high production costs, and cannot
respond adequately to meet the demand during pandemics.
Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was done
in two stages. In Stage I, we systematically reviewed the literature related to emerging cross-protective vaccines against
influenza relevant to several criteria of interest: answerability; cost of development, production and implementation;
efficacy and effectiveness; deliverability, affordability and sustainability; maximum potential impact on disease burden
reduction; acceptability to the end users and health workers; and effect on equity. In Stage II, we conducted an expert
opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international
policy makers and representatives of pharmaceutical companies). They answered questions from the CHNRI framework
and their “collective optimism” towards each criterion was documented on a scale from 0 to 100%.
Results: The experts expressed very high level of optimism for deliverability, impact on equity, and acceptability to
health workers and end users. However, they expressed concerns over the criteria of answerability, low
development cost, low product cost, low implementation cost, affordability and, to a lesser extent sustainability. In
addition they felt that the vaccine would have higher efficacy and impact on disease burden reduction on overall
influenza-associated disease rather than specifically influenza-associated pneumonia.
Conclusion: Although the landscape of emerging influenza vaccines shows several promising candidates, it is
unlikely that the advancements in the newer vaccine technologies will be able to progress through to large scale
production in the near future. The combined effects of continued investments in researching new vaccines and
improvements of available vaccines will hopefully shorten the time needed to the development of an effective
seasonal and pandemic influenza vaccine suitable for large scale production.
Background
Globally, acute lower respiratory infections (ALRI) are a
leading cause of morbidity and mortality in young children
[1,2]. Respiratory viruses are commonly associated with
ALRI episodes in young children [3]. Studies in the past
decade suggested that the burden of disease due to
hospital admissions for influenza associated ALRI
in young and very young children is substantial [4,5].
Influenza is the second most commonly identified patho-
gen in children with ALRI and resulted in about 20 million
new episodes of influenza-associated ALRI and 1 million
hospitalisations in children aged below 5 years in the year
2008. Ninety six percent of these episodes were in devel-
oping countries. An estimated 28,000 to 111,500 children
younger than 5 years of age died from influenza- asso-
ciated ALRI in 2008, with 99% of these deaths occurring
in developing countries. [6,7]. Apart from hospitalisations
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and deaths, influenza has significant economic conse-
quences on families, healthcare services and society [4,8].
Therefore, governments may see broader value in using an
influenza vaccine for example to avoid loss of work-days as
well as reducing medical visits and hospital care episodes.
There are about 1.2 billion people at high risk for
severe influenza outcomes who need an effective vaccine
of which 385 million are over 65 years of age, 140 million
are children under the age of five years, and 700 million
are with an underlying chronic medical condition [9].
Annual vaccination remains the most effective way to sig-
nificantly decrease the spread and subsequent mortality and
morbidity associated with influenza viruses. However, the
ability of the current egg-based inactivated vaccines to suc-
cessfully provide long-term immunity is limited by anti-
genic drift (minor mutations causing small changes in the
haemagglutinin gene); or the rarer antigenic shift (genetic
re-assortment between animal and human influenza
viruses; or a direct jump from animal species to humans of
a virus that has acquired the ability to easily spread from
human-to-human). Every year, the seasonal influenza vac-
cine is reformulated to match the circulating strains of the
virus. Moreover, the production of egg-based vaccines are
time and resource intensive and are unlikely to provide an
adequate response during pandemics [10]. The poor uptake
of the seasonal influenza vaccine (especially in high influ-
enza burden developing countries) is linked to the limited
production capacity in low resource settings and ultimately
impairs the much needed surge in influenza vaccine pro-
duction capacity during pandemics. The development of a
novel influenza vaccine providing long term cross-protec-
tion has remained a scientific challenge. We aimed to
review the existing literature, outlining the progress of the
emerging vaccines against influenza at all stages of develop-
ment; present the evidence regarding key issues surround-
ing these products and assess the level of collective
optimism of international experts over its priority status for
receiving investment support. The paper is presented as
part of a series of papers addressing emerging vaccines and
other interventions against pneumonia [11-16].
Methods
We used a modified Child Health and Nutrition Research
Initiative (CHNRI) methodology for setting priorities in
health research investments. The original CHNRI metho-
dology has been described in great detail [17-21] and
implemented in a variety of settings [22-27]. The modifica-
tion has been described in detail elsewhere [28] but is
summarized below.
CHNRI exercise – stage I: Identification and selection of
studies
We conducted a systematic literature review using the
following criteria: answerability, cost of development,
cost of product, cost of implementation, efficacy and
effectiveness, deliverability, affordability, sustainability,
maximum potential impact on disease burden reduction,
acceptability to health workers, acceptability to end users
and equity [28] (Figure 1). The following search terms:
influenza virus, vaccination, immunization, infants, and
children were used. The search was limited to Ovid
MEDLINE, Embase, Global Health, Web of Science,
LILACS, IndMed, and grey literature (SIGLE) databases
from July 2007 to June 2009 (updated in May 2012). A
large part of the review involved searching the websites
of individual pharmaceutical companies for details of
research, including clinical trials, or product updates on
vaccines in development. Relevant experts were also con-
tacted for information regarding the various influenza
vaccines under development. This was supplemented
with hand searching of online journals and scanning of
reference lists of identified citations. A total of 8021 arti-
cles were identified initially of which 81 articles were
found suitable for full-text review. The inclusion and
exclusion criteria are outlined in Table 1.
CHNRI exercise – stage II: An expert opinion exercise
We shared the initial review of the literature (as back-
ground material) with 20 experts prior to the meeting.
The list of chosen experts included five leading basic
scientists, five international public health researchers,
five international policy makers and five representatives
of pharmaceutical companies which manufactured influ-
enza vaccines. We initially offered participation to the
20 experts with the greatest impact of publications in
their area of expertise over the past 5 years (for basic
researchers and international public health researchers),
or for being affiliated to the largest pharmaceutical com-
panies. The policy makers and industry representatives
accepted our invitation on the condition of anonymity,
due to the sensitive nature of their involvement in such
exercises. About half of the experts were either affiliated
to institutions in developing countries or had previous
experience of working in developing country settings.
The experts met during September 7-13, 2009 in
Dubrovnik, Croatia, to conduct the 2nd stage of CHNRI
expert opinion exercise. The process of second-stage
CHNRI is shown in Figure 2. The literature review on
emerging interventions against childhood pneumonia
(CHNRI stage I) were presented formally (using power
point slides) using a structured format – the aforemen-
tioned CHNRI. After the evidence on a particular cri-
teria (e.g. answerability) was presented, all invited
experts discussed the evidence provided; the discussions
were facilitated by IR and HC. The experts then inde-
pendently answered questions from CHNRI framework
(Additional file 1) following published guidelines
[17-21].
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Results
We identified 40 articles in June 2009 (updated to 80
articles and product monographs in May 2012) for
inclusion. We have presented the updated review in this
paper. Currently 101 different influenza vaccines are in
various stages of development, of which 78 are yet to
enter Phase III clinical trials [29].
Answerabilty - Is the science behind the research
viable?
Adjuvanted egg-based inactivated vaccines (EBIV)
Adjuvanted vaccines (Figure 3) have been shown to be
antigen sparing and more immunogenic compared to
non-adjuvanted vaccines, and may allow increased pro-
duction capacity to meet global demand [30-32].
Figure 1 A summary of Stage I of the CHNRI process of evaluation of an emerging intervention (a systematic review of the key CHNRI
criteria) CHNRI- Child Health and Nutrition Research Initiative
Table 1 Details of eligibility criteria used for screening the studies
Inclusion criteria Exclusion Criteria
- Included research into influenza vaccine, or other vaccine that may bear resemblance to
future influenza vaccination programs
- Influenza vaccine candidate was not a focus
of the paper
- Vaccine research was targeted at children under 5 years - Vaccines targeted at the elderly
- Gave an indication of answerability, efficacy, effectiveness, deliverability, disease burden
reduction or impact on equity of a vaccine
- Papers not directly relating to vaccine
development and its impact
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Cell-cultured inactivated vaccines (CCIV)
CCIV (Figure 4) have been demonstrated to be equally
well tolerated and show potentially greater flexibility of
supply during periods of high demand compared to
EBIV [33-35]. Madin-Darby Canine Kidney (MDCK)
cells and Vero cells have been researched extensively
and candidate vaccines- Optaflu (Novartis) and Ceva-
pan (Baxter) are well tolerated and have gained regula-
tory approval in the EU [36,37]. Newer vaccines have
also shown great promise during clinical trials.
Although CCIV addresses many of the current limita-
tions faced by EBIV, their production capacity is largely
dependent on individual virus strains as some replicate
better than others in mammalian cells. This is also a
relatively new technology and requires more sophisti-
cated equipment such as a fermenter-based cell culture
either using suspension cells or a micro-carrier-based
culture [38].
Live-attenuated influenza vaccines (LAIV)
Current market-approved LAIVs are produced using the
egg-based method (Figure 5) and therefore share the
same advantages and limitations as EBIV. Drug compa-
nies are currently researching on developing LAIVs
using cell-based technology. These have been shown to
be safe and sufficient to produce a protective immune
response in adult humans during Phase I and Phase II
clinical trials and therefore might be an effective alterna-
tive to conventional EBIV [39-43].
Figure 2 A summary of Stage II of the CHNRI process of evaluation of an emerging intervention (an expert opinion exercise using the
9 CHNRI criteria) CHNRI- Child Health and Nutrition Research Initiative
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Recombinant (VLP) vaccines
In the case of recombinant vaccines, the answerability
would depend on the type of virus-like particles (VLP)
used. Similar to CCIVs, these vaccines can be rapidly pro-
duced in large quantities while avoiding the use of eggs.
Animal studies show that they are able to induce satisfac-
tory immune response that correlates to protection [44-49].
There are 19 companies currently developing different
types of recombinant vaccines, indicating that there is
great promise in the technology (Figure 6). Protein
Sciences’ insect cell vaccines have shown the most pro-
gress (currently in Phase II trials) and have demon-
strated a degree of cross protection against both
influenza A(H1N1) and A(H3N2) strains [50-55]. Vac-
cine manufacturers remain optimistic that recombinant
vaccines shall be able to meet the demands during pan-
demics. However, further research is required to evalu-
ate the answerability of this technology.
Figure 3 The current status of the research into emerging egg-based influenza vaccines WV- Inactivated Whole Virion
Figure 4 The current status of the research into emerging cell-cultured influenza vaccines MDCK- Madin-Darby Canine Kidney cells
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Universal/Vector-based/DNA vaccines
Most of these vaccines are currently in pre-clinical and
Phase I clinical trials (Figure 7, 8, 9). Therefore, more
research is needed to evaluate the feasibility of these
vaccines. Preliminary trials show that these vaccines are
able to provide broad protective immunity across differ-
ent influenza virus strains and are safe and well toler-
ated in animal and human studies [56-73].
Based on this evidence, the panel of experts expressed
concern over the ability of emerging cross-protective
influenza vaccines to satisfy the criterion of answerabil-
ity (score 61%) (Figure 10).
Efficacy - the impact of the vaccines under ideal
conditions
A recent Cochrane review reported that LAIVs have a
good relative efficacy – 80 (95% CI 68 to 87) percent in
children aged more than 2 years [74]. In comparison,
inactivated vaccines have a relatively lower efficacy – 59
(95% CI 41 to 71) percent in this age group [75,76]. In a
Figure 5 The current status of the research into emerging live attenuated influenza vaccines MDCK- Madin-Darby Canine Kidney cells
Figure 6 The current status of the research into recombinant influenza vaccines VLP- influenza virus like particles; HA- haemagglutinin;
rHA- recombinant haemagglutinin
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recent study, Johansson and colleagues demonstrated
that viral co-infections increase the severity and dura-
tion of hospitalisation in patients with bacterial pneu-
monia [83]. For children aged below 2 years, although
they reduce the risk for influenza by about a half, they
are not significantly more efficacious than a placebo.
Adjuvanted egg-based inactivated vaccines
On-going phase II and III clinical trials studying the
immunogenicity of adjuvanted vaccines have reported
higher immune response compared to the non-adju-
vanted formulation [30].
Cell-cultured inactivated vaccines
There are limited published data regarding the efficacy of
newer CCIVs currently in development. Market approved
CCIVs- Optaflu (Novartis) and Celvapan (Baxter) have
both demonstrated adequate immunogenicity in large
scale human studies and no serious adverse effects
(SAEs) were reported [36,37]. They have both been
approved by the European Medicines Agency (EMEA) in
2009. Both are undergoing phase III trials in the US.
Bharat Biotech’s HNVAC has been tested in one of the
largest phase I, II, and III clinical trials in India and has
been proven immunogenic and well tolerated [77].
Live-attenuated influenza vaccines (LAIV)
LAIVs are currently licenced for use in in healthy children
and adults between 2- 59 years old in Russia, India and
USA [78]. A meta-analyses comparing the immunogeni-
city of intranasally administered LAIV with egg-based TIV
in children (6 months to 17 years old) demonstrated the
superior efficacy of the LAIV compared to TIV [79].
Figure 7 The current status of the research into universal influenza vaccines NP- novel peptide; HA- haemagglutinin
Figure 8 The current status of the research into vector-based influenza vaccines MVA- modified vaccinia virus Ankara; MA- multi-antigen;
NP- nucleoprotein
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Recombinant (VLP) vaccines
VLP technology is relatively new and there are limited
published data on their efficacy. Protein Science Cor-
poration is developing seasonal (Flublok) and pandemic
(Panblok) influenza vaccines which have shown favour-
able immunogenicity and tolerability during Phase I and
II clinical trials [50,52,54]. Novavax’s H1N1 VLP vaccine
was well tolerated and immunogenic in a phase II clini-
cal trial carried out in more than 4000 subjects in Mex-
ico [55]. Medicago have also announced promising
Phase I trial results from the company’s plant cell based
H1 VLP and H5 VLP vaccines and they intend to pro-
ceed with Phase IIa trial in the US [80].
Universal vaccines
Limited data are available regarding the efficacy of univer-
sal vaccines. Merck, Generex and Sanofi Pasteur have cur-
rently halted their clinical trials. Phase I data reported in
February 2011 have found Dynavax’s universal candidate
vaccine (N8295) to be safe and generally well tolerated
alone or combined with H5N1 vaccine [58]. VaxInnate
recently reported that its candidate vaccine, Vax102, safely
produces an immune response in humans that should be
protective against all strains of influenza A [59]. Biondvax’s
Multimeric-001 universal vaccine has undergone phase IIa
trials and was shown to successfully activate immune
responses against the vaccine virus itself as well as the wild
against Influenza A and B virus strains. The trial also
demonstrated a higher antibody titre when co-adminis-
tered with 50% TIV dose compared to TIV alone [63].
Vector-based vaccines
These vaccine candidates are in early trial stages, there-
fore there are limited data regarding their efficacy.
Results from Erasmus, Emergent and CureLab’s preclini-
cal trials demonstrate that the vaccines induce strong
immune response to pandemic influenza virus antigens
in healthy mice [60-62,64,65]. Results from AlphaVax
Inc’s Phase I clinical trial in 2007 showed good immune
response in volunteers, which persisted for four months
[67]. Vaxin’s adenovirus-vectored vaccine and PaxVax’s
PXVX- 0103 showed similar results in Phase I trials
[68]. VaxArt Inc’s oral influenza vaccine has demon-
strated adequate antibody response in animal subjects
and is currently undergoing Phase I trials [69]. The Jen-
ner Institute’s MVA-NP+M1 vaccine has already suc-
cessfully progressed through a Phase I and Phase IIa
study in human subjects and is being researched in
combination with traditional TIV [70].
DNA vaccines
These vaccine candidates are in early phases of clinical
trials. In preclinical animal studies and Phase I human
trials, Inovio’s DNA vaccines demonstrated great poten-
tial of inducing immune response in healthy mice when
delivered with their proprietary electroporation DNA
delivery technique [72]. Data from Pfizer’s (previously
PowderMed) DNA vaccination showed that the vaccine
was well tolerated and induced sufficient antibody
response to the influenza A/H3 Panama/2007/99 virus
strain it was challenged with [81].
Based on this evidence, the experts were of the opi-
nion that the likelihood of efficacy of these emerging
cross-protective vaccines against influenza was high
(score 79%) but was rather low against pneumonia
(score 52%) (Figure 10).
Effectiveness - maximum burden reduction potential
In a recent meta-analysis, Jefferson and colleagues have
demonstrated that live attenuated vaccines have an over-
all effectiveness of 33% (RR in vaccinees 0.67; 95% CI
Figure 9 The current status of the research into DNA vaccines against influenza
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0.62 to 0.72), while inactivated vaccines have an overall
effectiveness of 36% (RR in vaccinees 0.64; 95% CI 0.54
to 0.76) [74]. The authors could not find any evidence
for children aged less than two years.
Immunisation with PCV7 has been shown to prevent
hospitalisation for pneumonia in children with seasonal
influenza – vaccine efficacy 45 (95% CI 14 to 64) per-
cent [82]. In a recent study, Johansson and colleagues
Figure 10 The results of Stage II CHNRI process – an expert opinion exercise assessing the potential usefulness of investment in
emerging influenza vaccines CHNRI- Child Health and Nutrition Research Initiative
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demonstrated that viral co-infection increase the severity
and duration of hospitalisation in patients with bacterial
pneumonia [83]. Thus, there is an unexplored potential
of utilizing influenza vaccines to reduce the disease bur-
den of childhood pneumonia [84]. A universal influenza
vaccine that can cover all the virus subtypes, and pro-
vide effective and long lasting protection, might have a
large impact on reducing the burden of childhood
pneumonia.
The experts felt that on the criterion of the maximum
potential impact on disease burden, the impact of a cross-
protective vaccine would be greater on influenza-related
mortality than overall pneumonia mortality- the median
potential effectiveness of the vaccines in reduction of over-
all pneumonia was 13%; (interquartile range 3-30% and
min. 0%, max 60%) compared to 60% for influenza-related
mortality (interquartile range 25-80% and min. 0%, max
90%) (Figure 10).
Deliverability, affordability and sustainability
This criterion takes into account the level of difficulty in
delivering a novel influenza vaccine, the infrastructure
and other resources available to implement the interven-
tion and also government capacity and partnership
requirements for achieving near-universal coverage with
this new intervention.
Egg-based inactivated vaccines
The egg-based technology has been used for over 60 years
and has proven to be an effective mode of production.
However, its sustainability is dependent heavily on the
supply of eggs and the estimated time required to establish
a large scale plant is 4 years [78]. The technology, although
established, is complex and requires advanced equipment
which may not be available in many developing countries
and therefore may not be sufficient to provide a compre-
hensive response to a pandemic outbreak [10].
Cell-cultured inactivated vaccines
The deliverability of CCIV has been compared exten-
sively with that of EBIV and has shown to have an
advantage in terms of production capacities and safety.
The technology may also be used to develop other types
of vaccines. However, it is a relatively new system with a
variable yield of viral titres depending on the influenza
virus strains [33,34]. Therefore, more comprehensive
studies are required to evaluate the long term sustain-
ability of this technology and its potential to preserve
global demands.
LAIV
The sustainability of current LAIV is limited by its
dependence on egg supply. The new cell-derived vaccine
may be able to overcome this and improve the long term
sustainability of LAIV. The aim is that it would be highly
scalable with low manufacturing cost and free from ani-
mal or microbial contaminants [40,41].
Recombinant/Universal/ Vector-based/DNA vaccines
The specific deliverability and sustainability of these vac-
cine technologies are unknown as they are still in early
trial stages. However, it is clear that they would require
advanced and highly individualised equipment and pro-
cessing plants which could take years to develop and
implement. Although the drug companies involved in
their production are positive regarding the sustainability
of the vaccines, it is still too early to predict their long
term results.
Should a candidate vaccine prove efficacious against
pneumonia, future studies should assess their suitability
for integration into an Expanded Programme of Immuni-
sation (EPI) schedule. If the aim is to reduce pneumonia
morbidity and mortality then vaccine administration
should be aimed at children aged below 2 years [84], pro-
vided that they are sufficiently immunogenic and protec-
tive. The administration, transportation and storage
should also complement those of the other EPI vaccines.
[85]. The five main areas of current research to simplify
administration are jet injection, intranasal spray, pulmon-
ary inhalation of aerosols, oral ingestion and cutaneous
administration (e.g. mechanical disruption of the stratum
corneum, coated microtines, hollow micro-needles, dis-
solving micro-needles) [29,86]. The experts were optimis-
tic (score over 80%) about the ability of the vaccine to
satisfy the criteria of deliverability (Figure 10).
Various funding mechanisms, such as the International
Finance Facility for Immunisation (IFFIm), the GAVI
Alliance and Advance Market Commitment (AMC) for
pneumococcal conjugate vaccines etc. exist for introduc-
tion and procurement of specific EPI vaccines to the least
developed countries. The creation of any additional fund
for influenza vaccines, unless it provides broad-spectrum
and long lasting protection against constantly mutating
viruses, is a challenge. The panel was also not optimistic
(score about 50% and 40% respectively) about the ability
to develop novel influenza vaccines at a low development
cost and low production cost respectively– and hence
were unsure whether vaccine prices could be kept low
(Figure 10). The main argument for high costs associated
with influenza vaccines is typically based on the require-
ment of annual reformulation and vaccination. Some
experts pointed out that the price of a vaccine in a given
country is often determined by negotiations between a
government and an industry. Industry representatives
explained that there were various elements to define a
price: total volume produced and sustainability and pre-
dictability of demand. UNICEF uses a range of prices for
developing country procurement. It was noted that only
a limited number of vaccine manufacturers are interested
in entering into UN and/or PAHO tenders and that
vaccine price for private use may be marked up by a
wholesaler and is influenced by intermediate sales and
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taxes which makes predicting the cost of both existing
and emerging vaccines complex.
Current deliverability of the trivalent vaccine is unable
to meet the enormous needs (see background) for several
reasons. First, due to constant change in viral strains, there
is a need for annual reformulation. Second, although vac-
cines stored in bulk are stable and could be used for
stock-pile, no data on the exact shelf-life of the vaccines
currently exist. Third, vaccines with virus types that are
not optimally matched to wild-type virus have relatively
lower efficacy than those with homologous strains [87],
and thus are generally inadequate for subsequent seasons.
Finally, although egg-based vaccine production is still the
most common production method, it is not efficient,
requiring 20 – 23 weeks for new vaccine production, as
opposed to recombinant vaccines, which potentially could
be produced in 8 – 12 weeks [88,89]. If Northern Hemi-
sphere manufacturers based production on global rather
than regional demand this would lead to a greater and
most constant level of demand which would encourage
facilities to increase vaccine production throughout the
year. Furthermore, local manufacturing capacity in devel-
oping countries could be built up, which would provide
surge potential for increased demand in times of pandemic
or even greater seasonal uptake. Overall, there was some
concern that even if the prices were kept low in the initial
phases by support from GAVI Alliance and other agencies,
high coverage with a novel cross-protective influenza vac-
cine might not be sustainable (score 75%) (Figure 10).
Acceptability
Over the last five years, there has been an increase in the
acceptability of influenza vaccines amongst both the
healthcare workers and end-users. First, there has been
significant expansion in global influenza vaccine manu-
facturing capacity, with seasonal vaccine production
increasing from 350 million doses in 2006 to around 900
million doses in 2009 [90]. The WHO has been engaged
in an influenza vaccine transfer technology transfer
initiative to help create regionally based, independent
and sustainable pandemic influenza vaccine production
capacity in developing countries. [29]. Some countries
with relatively low per capita GNIs such as Chile, Colum-
bia, Panama and Mexico have achieved relatively high
levels of distribution. Needle free delivery methods are
likely to simplify vaccine administration and improve
coverage in all settings [29]. The experts were highly
optimistic (score over 80%) that the emerging cross-pro-
tective influenza vaccines would be acceptable to both
the end-users and health workers (Figure 10).
Equity
This considers predicted effects on poor, high burden
populations within countries. [6] The score is high when
the experts agree that the resultant impact will reduce
health inequities between rich and poor social groups.
The lowest social classes typically suffer from dimin-
ished intervention coverage, weaker health services and
greater disease exposure. However, if the vaccine were
to be made available to those at highest risk of disease
(i.e. the most socio-economically deprived areas), there
are likely to be substantial reductions both in age-speci-
fic mortality and in health inequalities [91]. This study
highlights the importance of political will to ensure
access of efficacious vaccine to the lower income, higher
risk social sectors in order to achieve health equity. The
experts were very optimistic (score over 80%) of the
ability of the emerging cross-protective influenza vac-
cines to have a positive impact on equity (Figure 10).
Discussion
This paper summarises the available evidence required
for informing research and investment priority setting
on cross-protective emerging influenza vaccines. While
the experts expressed very high level of optimism for
deliverability, impact on equity, and acceptability to
health workers and end users, they expressed concerns
over answerability, low development cost, low product
cost, low implementation cost, affordability and, to a les-
ser extent sustainability. In addition they felt that the
vaccine would have higher efficacy and impact on dis-
ease burden reduction on overall influenza-associated
disease rather than specifically influenza-associated
pneumonia. In some cases low scores on some criteria
partly reflect lack of evidence. It is anticipated that in
November 2012, based on the current evidence, the
same panel of experts would score some of these criteria
(especially the low scoring ones like answerability) quite
differently.
This is the first time such an exercise has been
attempted to make a structured assessment of emerging
vaccines. The scores express the collective opinion of a
panel of 20 experts. While there is always an element of
uncertainty when predicting impact of interventions
which do not exist, we feel that the results would be
reproducible with another panel in a different setting.
There might be some biases in the literature search as
only we searched for studies published in English lan-
guage. Inclusion of experts from five pharmaceutical
companies manufacturing influenza vaccines and invest-
ing in research and development of emerging influenza
vaccines may have also contributed to some bias. How-
ever, this is unlikely to have altered the final scores
significantly.
Current research and developments are moving away
from the egg-based technology and into cell cultured
vaccines, which would effectively overcome the limita-
tions of egg-based productions. Cell-culture production
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capacity can be scaled up quickly when needed and the
product is free from animal contaminants. However, the
cost of developing cell-cultured influenza vaccines is
more expensive compared to egg-based production for
quantities less than 25 million doses per year. The tech-
nology is also relatively new with new regulatory paths
and therefore needs to be further refined in order to
achieve the same level of success as EBIV.
The developmental success and limitations of LAIV
are largely dependent on that of egg-based technology.
Although still in clinical trial phases, cell-derived LAIV
have shown promising results and may be able to
replace the conventional egg-based LAIV in the near
future. LAIV are administered intranasally and provides
an exciting platform for the development of newer
‘friendly use’ vaccine delivery methods.
Currently, the development of recombinant vaccines
using VLPs is one of the main focuses of the influenza
vaccine industry. The very fact that numerous drug com-
panies are currently researching this technology shows
that there is great confidence in the efficacy and deliver-
ability of these vaccines. VLP-produced vaccines are
quicker to manufacture and potentially cheaper than cur-
rently available influenza vaccines, making these the fore-
runner in the race to develop a new vaccine platform to
overcome the threat of a pandemic outbreak. However,
questions remain as to whether the technology will be
suitable for large scale production to overcome the pro-
duction constraint of current vaccine technologies.
The development of a universal influenza vaccine has
long been the ultimate goal of the industry. However,
the feasibility of developing such a vaccine remains
unclear as participating drug companies remain stagnant
in their clinical trials. If successfully produced, the vac-
cine will have the potential to offer recipients long term
and cross-protective immunisation against different
virus strains. However, the scientific challenges notwith-
standing, there are major economic and political impedi-
ments to the development of cross-protective influenza
vaccine. A truly cross-protective vaccine that confers
long-term protection (several years or more) would
completely change the entire influenza vaccine market.
The present market reflects many billions of dollars of
investment and is highly profitable. Even today, addi-
tional egg-based vaccine capacity is being added by
major manufacturers. A cross-protective influenza vac-
cine that confers long-term protection would represent
a direct and major threat to the established business
model. Such a novel vaccine would need to carry a very
high price tag to compensate for the massive losses in
income from the present annual vaccination model and
the cost of developing entirely new production facilities
(or retrofitting existing systems when feasible). There-
fore, there is actually very little motivation for industry-
sponsored research targeted at developing a universal
vaccine. If such a vaccine is eventually developed, it will
likely be the result of government and/or academic
research.
Early studies of vector based vaccines have shown to
increase the immunogenicity of traditional TIV and may
be used in combination with current vaccines to provide
a level of cross protection that is not characteristic of
conventional influenza vaccines. Similarly, DNA vaccines
are still in very premature stages of development and
therefore it is difficult to predict its potential outcome.
Although still in early stages, these vaccines show a
great amount of potential in clinical trials in terms of
their immunogenicity and production capacities.
Production and uptake of seasonal influenza vaccines is
an integral part of pandemic influenza preparedness plan-
ning. In order to meet the demands for a surge in vaccine
production during pandemics, technology transfer and
establishment of regional centres for vaccine manufacture
in resource poor settings have already been incorporated
as part of the Global Action Plan (GAP) for influenza vac-
cines. However, integration of seasonal influenza vaccine
into the EPI schedule (along with the vaccines against bac-
terial pneumonia) remains the key to decreasing childhood
pneumonia morbidity and mortality.
Conclusions
In summary, it is unlikely that the advancements in the
newer vaccine technologies will be able to progress
through to large scale production in the near future.
Although arduous and time consuming, more clinical
studies are needed to evaluate the viability and efficacy
of these vaccines and their role in decreasing the global
disease burden of influenza. The combined effects of
continued investments in researching new vaccines and
improvements of available vaccines will hopefully
shorten the time needed to the development of an effec-
tive seasonal and pandemic influenza vaccine suitable
for large scale production.
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